IL1B and colorectal cancer: On the one hand, they can significantly inhibit NF-κ B/p65 signaling pathway activity, thereby down-regulating IL-6, TNF-α and IL-1β and up-regulating IL-10 in the serum of patients with colorectal cancer, which further reduces the inflammatory response associated with colorectal cancer.